NCT01259934View on ClinicalTrials.gov

Nordic Adjuvant IFN Melanoma Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

855

Participants

Timeline

Start Date

November 30, 1996

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
MelanomaAdjuvant Therapy
Interventions
DRUG

Interferon-alpha2b - 1 year

Induction: IFN-alpha2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alpha2b, 10 MU (flat dose), 3 days/week, SC, 12 months

DRUG

Interferon-alpha2b - 2 years

Induction: IFN-alfa2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alfa2b, 10 MU (flat dose), 3 days/week, SC, 24 months

Trial Locations (1)

S-171 76

Karolinska Institutet, Karolinska University Hospital,, Stockholm

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Karolinska Institutet

OTHER

NCT01259934 - Nordic Adjuvant IFN Melanoma Trial | Biotech Hunter | Biotech Hunter